KALA BIO, Inc.

NasdaqCM:KALA Stock Report

Market Cap: US$47.0m

KALA BIO Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Avi Minkowitz

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure6.4yrs
Board average tenureless than a year

Recent management updates

Recent updates

Seeking Alpha • Oct 20

Kala Pharmaceuticals to execute reverse stock split

Kala Pharmaceuticals (NASDAQ:KALA) will implement a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares, effective at 4:05 p.m. on October 20, 2022. Every 50 shares of Kala’s (KALA) issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. The split will reduce the number of shares of common stock outstanding from 73,208,140 shares to ~1,464,163 shares, subject to adjustment for the rounding up of fractional shares. The stock will will begin trading on a split-adjusted basis when the market opens on Friday, October 21, 2022. KALA shares are down over 2% premarket
Seeking Alpha • Aug 10

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals (NASDAQ:KALA) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.36 (+36.8% Y/Y) and the consensus Revenue Estimate is $2.02M (-33.8% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

CEO

Avi Minkowitz (37 yo)

less than a year
Tenure

Mr. Avi Minkowitz is CEO & CFO at KALA BIO, Inc. from February 2, 2026. He is Director of KALA BIO, Inc. from January 2026. Mr. Minkowitz serves as Director at International Star, Inc. since October 20, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Mary Reumuth
Treasurer & Secretary12.3yrsUS$1.38mno data
Avi Minkowitz
CEO, CFO & Directorless than a yearno datano data
Justin Hanes
Founder & Chair of the Scientific Advisory Boardno datano datano data
Jill Steier
Executive Director of Investor Relations & Corporate Communications4.8yrsno datano data
Vincent Kosewski
Senior VP of Manufacturing & Supply Chain Management8.8yrsno datano data
Francis Mah
Chief Medical Advisor3.2yrsno datano data
Josiah Craver
Senior VP & Corporate Controller4.1yrsno datano data
Carl Rennie
Executive Director of Account Management8yrsno datano data
Patrick Bedell
Executive Director of Trade & Alternate Channels8yrsno datano data
6.4yrs
Average Tenure
50yo
Average Age

Experienced Management: KALA's management team is seasoned and experienced (6.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Avi Minkowitz
CEO, CFO & Directorless than a yearno datano data
Justin Hanes
Founder & Chair of the Scientific Advisory Boardno datano datano data
Jonathan Silverstein
Board Observer10.1yrsno datano data
Peter Hutt
Member of Scientific Advisory Boardno datano datano data
Ronald Krall
Member of Scientific Advisory Boardno datano datano data
Bennett Shapiro
Member of Scientific Advisory Boardno datano datano data
Colin Gardner
Member of Scientific Advisory Boardno datano datano data
Brendan Purdy
Independent Directorless than a yearno datano data
Yonatan Colman
Independent Directorless than a yearno datano data
Chaim Berger
Independent Directorless than a yearno datano data
Hillel Posen
Independent Directorless than a yearno datano data
0.3yrs
Average Tenure
41.5yo
Average Age

Experienced Board: KALA's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 22:03
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

KALA BIO, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Biren AminJefferies LLC
Christopher NeyorJ.P. Morgan